Download PDF
Semin Thromb Hemost 2012; 38(06): 600-612
DOI: 10.1055/s-0032-1321491
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Quality in Molecular Biology Testing for Inherited Thrombophilia Disorders

Peter C. Cooper
1   Coagulation Laboratory, Sheffield Haemophilia and Thrombosis Centre
,
Anne C. Goodeve
2   Department of Cardiovascular Science, Haemostasis Research Group, University of Sheffield, Sheffield, United Kingdom
3   Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom
,
Nicholas J. Beauchamp
3   Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
20 August 2012 (online)

    Permissions and Reprints

Abstract

As the understanding of the genetic basis of the inherited thrombophilias has increased over recent years, their routine diagnostic genetic analysis has also matured. This review considers methods used to test for the factor V (F5) Leiden mutation and prothrombin 20210A (F2 c.*97G>A) allele, and analysis of the SERPINC1, PROC, and PROS1 genes in cases of antithrombin, protein C (PC), and protein S (PS) deficiency, respectively. Issues relating to quality are explored, highlighting where analytical and sample handling errors may occur. Detection of the factor V Leiden mutation and the prothrombin c.*97G>A allele are best performed using real-time polymerase chain reaction analysis as this relatively simple technique allows their discrimination from rare variants of neighboring nucleotides; not possible using the more time-consuming restriction digestion assays. With the advent of low-cost and high-throughput sequence analysis, direct sequencing has become the first-line method to provide a definitive diagnosis of inherited, rather than acquired, deficiencies. Large cohort studies have shown that antithrombin and PC mutations are identified in between 61 and 87% of patients, whereas the detection rate in PS deficiency is substantially lower in around 40% of patients. Large gene deletions make up between 7 and 10% of PS and antithrombin mutations and only 1% of PC mutations, but it is suggested that dosage analysis techniques such as multiplex ligation-dependent probe amplification should be used for all three genes as part of routine analysis to ensure mutations are not missed. Best practice guidelines are available from EuroGentest covering a wide variety of the issues raised in this review and all laboratories should participate in appropriate external quality assurance schemes to ensure they continue to offer high quality service.

Keywords

mutation - polymorphism - genetic analysis - external quality assessment - quality control
 

  • References

  • 1 Heit JA, Silverstein MD, Mohr DN , et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86 (1) 452-463
    PubMedGoogle Scholar
  • 2 Heit JA. Risk factors for venous thromboembolism. Clin Chest Med 2003; 24 (1) 1-12
    CrossrefPubMedGoogle Scholar
  • 3 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
    PubMedGoogle Scholar
  • 4 Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem 1976; 251 (2) 355-363
    PubMedGoogle Scholar
  • 5 Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16 (4) 698-706
    CrossrefPubMedGoogle Scholar
  • 6 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68 (5) 1370-1373
    CrossrefPubMedGoogle Scholar
  • 7 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311 (24) 1525-1528
    CrossrefPubMedGoogle Scholar
  • 8 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90 (3) 1004-1008
    CrossrefPubMedGoogle Scholar
  • 9 Bertina RM, Koeleman BPC, Koster T , et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369 (6475) 64-67
    CrossrefPubMedGoogle Scholar
  • 10 Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88 (1) 219-222
    CrossrefPubMedGoogle Scholar
  • 11 Zivelin A, Griffin JH, Xu X , et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89 (2) 397-402
    PubMedGoogle Scholar
  • 12 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-3703
    CrossrefPubMedGoogle Scholar
  • 13 Zivelin A, Mor-Cohen R, Kovalsky V , et al. Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. Blood 2006; 107 (12) 4666-4668
    CrossrefPubMedGoogle Scholar
  • 14 Lindqvist PG, Svensson PJ, Dahlbäck B, Marsál K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss—a possible evolutionary selection mechanism. Thromb Haemost 1998; 79 (1) 69-73
    PubMedGoogle Scholar
  • 15 Lindqvist PG, Zöller B, Dahlbäck B. Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden—an evolutionary advantage?. Thromb Haemost 2001; 86 (4) 1122-1123
    PubMedGoogle Scholar
  • 16 Lindqvist PG, Dahlbäck B. Carriership of factor V Leiden and evolutionary selection advantage. Curr Med Chem 2008; 15 (15) 1541-1544
    CrossrefPubMedGoogle Scholar
  • 17 Hille ETM, Westendorp RGJ, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89 (6) 1963-1967
    PubMedGoogle Scholar
  • 18 Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21 (5) 731-738
    CrossrefPubMedGoogle Scholar
  • 19 Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost 2009; 102 (2) 360-370
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Tait RC, Walker ID, Perry DJ , et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87 (1) 106-112
    CrossrefPubMedGoogle Scholar
  • 21 Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126 (11) 1326-1336
    PubMedGoogle Scholar
  • 22 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58 (4) 1094
    PubMedGoogle Scholar
  • 23 Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blombäck N. Discrepancy between antithrombin activity methods revealed in antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?. Blood 2002; 99 (6) 2271-2272
    CrossrefPubMedGoogle Scholar
  • 24 Corral J, Hernandez-Espinosa D, Soria JM , et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109 (10) 4258-4263
    CrossrefPubMedGoogle Scholar
  • 25 Andrew M, Paes B, Milner R , et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (1) 165-172
    PubMedGoogle Scholar
  • 26 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80 (8) 1998-2005
    PubMedGoogle Scholar
  • 27 Tait RC, Walker ID, Islam SI , et al. Age related changes in protein C activity in healthy adult males. Thromb Haemost 1991; 65 (3) 326-327
    PubMedGoogle Scholar
  • 28 Said JM, Ignjatovic V, Monagle PT, Walker SP, Higgins JR, Brennecke SP. Altered reference ranges for protein C and protein S during early pregnancy: implications for the diagnosis of protein C and protein S deficiency during pregnancy. Thromb Haemost 2010; 103 (5) 984-988
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Walker I, Greaves M, Preston FE. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114 (3) 512-528
    CrossrefPubMedGoogle Scholar
  • 30 Preston RJ, Morse C, Murden SL, Brady SK, O'Donnell JS, Mumford AD. The protein C omega-loop substitution Asn2Ile is associated with reduced protein C anticoagulant activity. Br J Haematol 2009; 144 (6) 946-953
    CrossrefPubMedGoogle Scholar
  • 31 Sthoeger D, Nardi M, Karpatkin M. Protein S in the first year of life. Br J Haematol 1989; 72 (3) 424-428
    CrossrefPubMedGoogle Scholar
  • 32 Serra J, Sales M, Chitolie A , et al. Multicentre evaluation of IL Test Free PS: a fully automated assay to quantify free protein S. Thromb Haemost 2002; 88 (6) 975-983
    PubMedGoogle Scholar
  • 33 Szecsi PB, Jørgensen M, Klajnbard A, Andersen MR, Colov NP, Stender S. Haemostatic reference intervals in pregnancy. Thromb Haemost 2010; 103 (4) 718-727
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84 (4) 1031-1035
    PubMedGoogle Scholar
  • 35 Koeleman BPC, van Rumpt D, Hamulyák K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?. Thromb Haemost 1995; 74 (2) 580-583
    PubMedGoogle Scholar
  • 36 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72 (6) 880-886
    PubMedGoogle Scholar
  • 37 Tripodi A, Chantarangkul V, Mannucci PM. Hyperprothrombinemia may result in scquired activated protein C reistance. Blood 2000; 96 (9) 3295-3296
    PubMedGoogle Scholar
  • 38 Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. ACMG Factor V Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3 (2) 139-148
    CrossrefPubMedGoogle Scholar
  • 39 Denson KW, Reed SV, Haddon ME. The modified APC resistance test. Thromb Haemost 1995; 74 (3) 995
    PubMedGoogle Scholar
  • 40 Simioni P, Castoldi E, Lunghi B, Tormene D, Rosing J, Bernardi F. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005; 106 (7) 2363-2365
    CrossrefPubMedGoogle Scholar
  • 41 Cooper PC, Cooper SM, Smith JM, Kitchen S, Makris M. Evaluation of the Roche LightCycler: a simple and rapid method for direct detection of factor V Leiden and prothrombin G20210A genotypes from blood samples without the need for DNA extraction. Blood Coagul Fibrinolysis 2003; 14 (5) 499-503
    CrossrefPubMedGoogle Scholar
  • 42 Parks SB, Popovich BW, Press RD. Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes. Am J Clin Pathol 2001; 115 (3) 439-447
    CrossrefPubMedGoogle Scholar
  • 43 Mahadevan MS, Benson PV. Factor V null mutation affecting the Roche LightCycler factor V Leiden assay. Clin Chem 2005; 51 (8) 1533-1535
    CrossrefPubMedGoogle Scholar
  • 44 Castoldi E, Kalafatis M, Lunghi B , et al. Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998; 80 (3) 403-406
    PubMedGoogle Scholar
  • 45 Kim HJ, Kim DK, Yoo KY , et al. Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array. Haematologica 2012; 97 (2) 304-309
    CrossrefPubMedGoogle Scholar
  • 46 de la Morena-Barrio ME, Antón AI, Martínez-Martínez I , et al. Regulatory regions of SERPINC1 gene: identification of the first mutation associated with antithrombin deficiency. Thromb Haemost 2012; 107 (3) 430-437
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Luxembourg B, Delev D, Geisen C , et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105 (4) 635-646
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Picard V, Chen JM, Tardy B , et al. Detection and characterisation of large SERPINC1 deletions in type I inherited antithrombin deficiency. Hum Genet 2010; 127 (1) 45-53
    CrossrefPubMedGoogle Scholar
  • 49 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14 (6) 1229-1239
    CrossrefPubMedGoogle Scholar
  • 50 Gandrille S, Aiach M. Identification of mutations in 90 of 121 consecutive symptomatic French patients with a type I protein C deficiency. The French INSERM Network on Molecular Abnormalities Responsible for Protein C and Protein S deficiencies. Blood 1995; 86 (7) 2598-2605
    PubMedGoogle Scholar
  • 51 García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis of protein S deficiency. Thromb Haemost 2007; 98 (3) 543-556
    PubMedGoogle Scholar
  • 52 Duebgen S, Kauke T, Marschall C , et al. Genotype and laboratory and clinical phenotypes of protein s deficiency. Am J Clin Pathol 2012; 137 (2) 178-184
    CrossrefPubMedGoogle Scholar
  • 53 Emadi A, Crim MT, Brotman DJ , et al. Analytic validity of genetic tests to identify factor V Leiden and prothrombin G20210A. Am J Hematol 2010; 85 (4) 264-270
    CrossrefPubMedGoogle Scholar
  • 54 Libby EN, Booker JK, Gulley ML, Garcia D, Moll S. False-negative factor V Leiden genetic testing in a patient with recurrent deep venous thrombosis. Am J Hematol 2006; 81 (4) 284-289
    CrossrefPubMedGoogle Scholar
  • 55 Preston FE, Kitchen S, Jennings I, Woods TAL. A UK National External Quality Assessment scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost 1999; 82 (5) 1556-1557
    PubMedGoogle Scholar
  • 56 Hertzberg M, Neville S, Favaloro E, McDonald D. External quality assurance of DNA testing for thrombophilia mutations. Am J Clin Pathol 2005; 123 (2) 189-193
    CrossrefPubMedGoogle Scholar
  • 57 Tripodi A, Chantarangkul V, Menegatti M, Tagliabue L, Peyvandi F. Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. Clin Chem 2005; 51 (7) 1310-1311
    CrossrefPubMedGoogle Scholar
  • 58 Castoldi E, Duckers C, Radu C , et al. Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma. J Thromb Haemost 2011; 9 (5) 959-968
    CrossrefPubMedGoogle Scholar
  • 59 Castaman G, Giacomelli SH, Mancuso ME , et al. Deep intronic variations may cause mild hemophilia A. J Thromb Haemost 2011; 9 (8) 1541-1548
    CrossrefPubMedGoogle Scholar
  • 60 Tsai CJ, Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM, Nussinov R. Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol 2008; 383 (2) 281-291
    CrossrefPubMedGoogle Scholar
  • 61 Goodeve AC, Reitsma PH, McVey JH. Working Group on Nomenclature of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Nomenclature of genetic variants in hemostasis. J Thromb Haemost 2011; 9 (4) 852-855
    CrossrefPubMedGoogle Scholar
  • 62 Hellen B. Splice Site Tools: A Comparative Analysis Report. Manchester: National Genetics Reference Laboratory; 2009
    Google Scholar
  • 63 Beauchamp NJ, Daly ME, Makris M, Preston FE, Peake IR. A novel mutation in intron K of the PROS1 gene causes aberrant RNA splicing and is a common cause of protein S deficiency in a UK thrombophilia cohort. Thromb Haemost 1998; 79 (6) 1086-1091
    PubMedGoogle Scholar
  • 64 Perry DJ, Goodeve A, Hill M, Jennings I, Kitchen S, Walker I. UK NEQAS for Blood Coagulation. The UK National External Quality Assessment Scheme (UK NEQAS) for molecular genetic testing in haemophilia. Thromb Haemost 2006; 96 (5) 597-601
    PubMedGoogle Scholar
  • 65 Castaldo G, Cerbone AM, Guida A , et al. Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy. Thromb Haemost 2012; 107 (4) 673-680
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Pavlova A, El-Maarri O, Luxembourg B , et al. Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography. Haematologica 2006; 91 (9) 1264-1267
    PubMedGoogle Scholar
  • 67 David D, Ferreira C, Ventura C, Freire I, Moreira I, Gago T. Genetic defects in Portuguese families with inherited protein C deficiency. Thromb Res 2011; 128 (3) 299-302
    CrossrefPubMedGoogle Scholar
  • 68 Rovida E, Merati G, D'Ursi P , et al. Identification and computationally-based structural interpretation of naturally occurring variants of human protein C. Hum Mutat 2007; 28 (4) 345-355
    CrossrefPubMedGoogle Scholar
  • 69 Kuismanen K, Levo A, Vahtera E , et al. Genetic background of type I protein C deficiency in Finland. Thromb Res 2006; 118 (5) 603-609
    CrossrefPubMedGoogle Scholar
  • 70 Alhenc-Gelas M, Canonico M, Morange PE, Emmerich J. Geht Genetic Thrombophilia Group. Protein S inherited qualitative deficiency: novel mutations and phenotypic influence. J Thromb Haemost 2010; 8 (12) 2718-2726
    CrossrefPubMedGoogle Scholar
  • 71 Ten Kate MK, Platteel M, Mulder R , et al. PROS1 analysis in 87 pedigrees with hereditary protein S deficiency demonstrates striking genotype-phenotype associations. Hum Mutat 2008; 29 (7) 939-947
    CrossrefPubMedGoogle Scholar
  • 72 Biguzzi E, Razzari C, Lane DA , et al; Protein S Italian Team. Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study. Hum Mutat 2005; 25 (3) 259-269
    CrossrefPubMedGoogle Scholar
  • 73 Lippi G, Favaloro EJ, Plebani M. Direct-to-consumer testing: more risks than opportunities. Int J Clin Pract 2011; 65 (12) 1221-1229
    CrossrefPubMedGoogle Scholar